Abstract Search

ea0099oc2.2 | Oral Communications 2: Calcium and Bone | Part I | ECE2024

Sustained improvement in renal function with palopegteriparatide in adults with chronic hypoparathyroidism: 2-year results from the phase 3 PaTHway trial

Schwarz Peter , Rejnmark Lars , Gosmanova Elvira , Khan Aliya , Makita Noriko , Imanishi Yasuo , Takeuchi Yasuhiro , Sprague Stuart , Shoback Dolores M. , Kohlmeier Lynn , Rubin Mishaela , Palermo Andrea , Gagnon Claudia , Tsourdi Elena , Zhao Carol , Makara Michael , Ominsky Michael , Lai Bryant , Ukena Jenny , Sibley Christopher , Shu Aimee

Hypoparathyroidism is an endocrine disease caused by insufficient levels of parathyroid hormone (PTH). Individuals with chronic hypoparathyroidism managed with conventional therapy (active vitamin D and calcium) are at increased risk for renal complications and declines in renal function. In clinical trials, palopegteriparatide treatment enabled independence from conventional therapy (no active vitamin D and ≤600 mg/day elemental calcium) and maintained serum biochemistr...

1 shares

Endocrine Abstracts

Sustained improvement in renal function with palopegteriparatide in adults with chronic hypoparathyroidism: 2-year results from the phase 3 PaTHway trial

BiosciAbstracts